13-Jul-2026
Canaccord Genuity Sticks to Their Hold Rating for InMode (INMD)
TipRanks (Tue, 14-Jul 7:15 AM ET)
Analyst Maintains Hold on InMode Amid Takeover Uncertainty and Limited Profitability Visibility
TipRanks (Tue, 14-Jul 6:45 AM ET)
InMode Faces Court Challenge Over Board Independence and Takeover Review
TipRanks (Mon, 13-Jul 1:19 PM ET)
Analysts Offer Insights on Healthcare Companies: Regeneron (REGN) and InMode (INMD)
TipRanks (Mon, 13-Jul 9:10 AM ET)
InMode expects Q2 revenue above estimates
Seeking Alpha News (Mon, 13-Jul 7:09 AM ET)
PRNewswire (Mon, 13-Jul 7:00 AM ET)
InMode Faces Multiple Unsolicited Acquisition Proposals
TipRanks (Fri, 10-Jul 7:27 AM ET)
InMode Confirms Receipt of Unsolicited Proposal
PRNewswire (Fri, 10-Jul 7:00 AM ET)
Steel Partners offers to acquire InMode at $16.75 per share cash deal; stock rises premarket
Seeking Alpha News (Thu, 9-Jul 9:41 AM ET)
Steel Partners Offers to Acquire InMode for $16.75 Per Share in Cash
Business Wire (Thu, 9-Jul 8:35 AM ET)
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF, and Morpheus8, among others. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia, Israel, and other regions.
Inmode Ltd. - trades on the NASDAQ stock market under the symbol INMD.
As of July 13, 2026, INMD stock price declined to $15.15 with 635,937 million shares trading.
INMD has a beta of 0.60, meaning it tends to be less sensitive to market movements. INMD has a correlation of 0.07 to the broad based SPY ETF.
INMD has a market cap of $870.83 million. This is considered a Small Cap stock.
Last quarter Inmode Ltd. - reported $82 million in Revenue and $.25 earnings per share. This beat revenue expectation by $2 million and missed earnings estimates by -$.08.
In the last 3 years, INMD traded as high as $48.25 and as low as $12.72.
The top ETF exchange traded funds that INMD belongs to (by Net Assets): IEFA, SCZ, IXUS, IZRL, AVDV.
INMD has underperformed the market in the last year with a return of +3.0%, while the SPY ETF gained +21.3%. In the last 3 month period, INMD fell short of the market, returning +8.3%, while SPY returned +9.5%. However, in the most recent 2 weeks INMD has outperformed the stock market by returning +2.8%, while SPY returned +1.1%.
INMD support price is $15.00 and resistance is $15.56 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INMD shares will trade within this expected range on the day.
